Reuters [1] |
'New Era' of Type 2 Diabetes Treatment as LEADER Unveiled? [2]
Medscape NEW ORLEANS — Details of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results—A Long Term Evaluation (LEADER) trial of the glucose-lowering drug liraglutide (Victoza, Novo Nordisk), showing that it significantly … Novo diabetes drug cuts heart risks by less-than-hoped 13 percentage [1]Reuters Novo Nordisk Drug Cuts Diabetic Deaths, But Not Enough For Wall Street [3]Investor’s Business Daily GLP-1 Drug Cuts Heart Risk in Diabetes [4]MedPage Today The Diabetes Times [5] –Bloomberg [6] all 59 news articles » [7] |
More details can be found at www.diabeteshowto.com [8]